Kaufman Rossin Wealth’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$467K Buy
1,785
+733
+70% +$188K 0.19% 55
2026
Q2
$263K Sell
1,052
-30
-3% -$6.45K 0.12% 83
2026
Q1
$235K Sell
1,082
-278
-20% -$61.7K 0.13% 89
2025
Q4
$311K Sell
1,360
-7
-0.5% -$1.6K 0.16% 100
2025
Q3
$317K Buy
1,367
+281
+26% +$57.2K 0.17% 91
2025
Q2
$202K Sell
1,086
-114
-10% -$21.2K 0.13% 133
2025
Q1
$251K Buy
1,200
+23
+2% +$4.47K 0.18% 109
2024
Q4
$209K Buy
+1,177
New +$216K 0.22% 35

Other funds holding ABBV

Kaufman Rossin Wealth's ABBV Position: Q3 2026 in Review

Kaufman Rossin Wealth increased its AbbVie (ABBV) stake by 70% in Q3 2026, buying an estimated $188K and bringing the position to 1,785 shares worth $467K. The position accounts for 0.19% of the portfolio, ranked #55.

Kaufman Rossin Wealth first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. 4,285 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Kaufman Rossin Wealth held 1,785 shares of AbbVie worth $467K as of Q3 2026.
  • Kaufman Rossin Wealth bought 733 AbbVie shares in Q3 2026, an estimated $188K.
  • AbbVie made up 0.19% of Kaufman Rossin Wealth's portfolio in Q3 2026, its #55 holding.
  • Kaufman Rossin Wealth first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
  • 4,285 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Kaufman Rossin Wealth's 13F filing for Q3 2026, filed 19 Oct 2026.